The Er/Ki-67 Proportion in Breast Tumours - An Immunohistochemical Study

Area of Science:

• Oncology
• Pathology
• Endocrinology

Background:

• Breast tumors are categorized as benign, proliferative, or invasive.
• Estrogen hormone significantly impacts tumor growth and progression.
• Estrogen Receptor (ER) status and Ki-67 are crucial prognostic factors.

Purpose of the Study:

• To assess variations in ER and Ki-67 expression across benign, proliferative, and malignant breast lesions.
• To evaluate the ER+/Ki-67+ ratio as a differentiating marker.

Main Methods:

• Histopathological analysis of 15 samples each for benign, proliferative, and invasive breast tumors.
• Calculation of the ER+/Ki-67+ ratio and statistical analysis (Student's t-test).
• Correlation analysis between ER and Ki-67 positivity using Pearson's coefficient.

Main Results:

• Mean ER+/Ki-67+ ratios were 0.81 (benign), 0.87 (proliferative), and 1.42 (invasive).
• Significant differences in ER+/Ki-67+ ratios were found between malignant and both benign/proliferative categories (p<0.05).
• Significant correlation between ER and Ki-67 observed in proliferative and malignant categories, but not benign.

Conclusions:

• The ER+/Ki-67+ ratio is a significant indicator for differentiating invasive breast cancer.
• This ratio can effectively distinguish invasive cancers from benign and proliferative breast tumors.
• ER and Ki-67 expression patterns offer valuable insights into breast tumor behavior.